Clinical Trials Logo

Clinical Trial Summary

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.


Clinical Trial Description

Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04216550
Study type Observational [Patient Registry]
Source The First Affiliated Hospital of Zhengzhou University
Contact Zhenyu Zhang, Dr.
Phone +86 17839973727
Email fcczhangzy1@zzu.edu.cn
Status Recruiting
Phase
Start date January 1, 2018
Completion date June 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05045027 - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Early Phase 1
Not yet recruiting NCT04562077 - Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
Active, not recruiting NCT05611645 - Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence Phase 2
Completed NCT04089449 - A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas Phase 1
Active, not recruiting NCT03213678 - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03698994 - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Recruiting NCT05406700 - Niraparib In Recurrent IDH 1/2 Gliomas Early Phase 1
Recruiting NCT05660369 - CARv3-TEAM-E T Cells in Glioblastoma Phase 1
Recruiting NCT03796273 - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Early Phase 1
Terminated NCT05297864 - PARP Inhibition for Gliomas (PI-4G or π4g) Phase 2
Not yet recruiting NCT06397560 - PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial N/A
Completed NCT01580969 - Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma Phase 1/Phase 2
Recruiting NCT03155620 - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Phase 2
Recruiting NCT04943718 - Personalized Vaccine for Patients With Recurrent Malignant Glioma Phase 1
Active, not recruiting NCT04164901 - Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Phase 3
Active, not recruiting NCT03212274 - Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Phase 2
Recruiting NCT04740190 - Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd Phase 2